Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

June 26, 2017

Study Completion Date

June 26, 2017

Conditions
Atopic Dermatitis
Interventions
DRUG

CD5024 0.3% cream

Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm\^2) once daily for 6 weeks.

DRUG

Placebo

Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm\^2 once daily for 6 weeks.

Trial Locations (5)

L5H 1G9

Galderma Investigational Site (#8581), Mississauga

L4B 1A5

Galderma Investigational Site (# 8338), Richmond Hill

L4C 9M7

Galderma Investigational Site (#8587), Richmond Hill

N8W 5L7

Galderma Investigational Site (# 8060), Windsor

H2K 4L5

Galderma Investigational Site (#8089), Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galderma R&D

INDUSTRY

NCT03250624 - Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis | Biotech Hunter | Biotech Hunter